Filtered By:
Specialty: Endocrinology
Management: Health Insurance
This page shows you your search results in order of date.
Order by Relevance | Date
Total 154 results found since Jan 2013.
Treatment Persistence and Medication Switch Associated with Subsequent Fractures after Osteoporotic Fractures
J Clin Endocrinol Metab. 2023 Aug 1:dgad449. doi: 10.1210/clinem/dgad449. Online ahead of print.ABSTRACTThe study examined the association between persistence in anti-osteoporotic medication (AOM) and subsequent fractures, allowing for medication switching among patients with osteoporotic fractures. This retrospective cohort study used Taiwan National Health Insurance claims data. We selected patients who initiated AOM between 2013 and 2016. Treatment persistence was defined as whether the patients were on any AOM on a given day of interest with a 45-day grace period. Medication switch was allowed for persistence if remain...
Source: The Journal of Clinical Endocrinology and Metabolism - August 1, 2023 Category: Endocrinology Authors: Sung-Yen Lin Wei-Ju Chen Chieh-Ko Ku Yi-Ming Chen Chung-Hwan Chen Li-Nien Chien Source Type: research
Effect of SGLT2 inhibitors versus DPP4 inhibitors on major and non-major osteoporotic fracture risks among general and high-risk type 2 diabetes patients: A nationwide retrospective cohort study
CONCLUSION: - This study adds supporting real-world evidence for SGLT2is-associated bone safety for a wide range of fractures, which promotes the rational use of SGLT2is in routine care and highlights the importance of the close monitoring of patients with high fracture risks to maximize treatment benefits while reducing undesirable effects.PMID:37451539 | DOI:10.1016/j.diabet.2023.101465
Source: Diabetes and Metabolism - July 14, 2023 Category: Endocrinology Authors: Zi-Yang Peng Yao-Tseng Wang Chin-Sung Chang Chih-Hsing Wu Huang-Tz Ou Source Type: research
